Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27487465 | 0.85 | NAMPT (0.43) | NAMPTTLR8HDAC3HDAC1HDAC2 | |
| SCHEMBL5025530 | 0.84 | NAMPT (0.42) | NAMPTTLR8HDAC3HDAC1HDAC2 | |
| SCHEMBL5015503 | 0.84 | CYP2A6 (0.44) | NAMPTHDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL5017381 | 0.84 | NAMPT (0.42) | NAMPTTLR8HDAC3HDAC1HDAC2 | |
| SCHEMBL2126019 | 0.83 | HDAC3 (0.46) | NAMPTHDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL27535692 | 0.82 | CYP2A6 (0.44) | NAMPTMAPTARCYP2A6CYP2C9 | |
| SCHEMBL4260991 | 0.81 | FYN (0.43) | MAPTARCYP2A6CYP2C9CYP2B6 | |
| SCHEMBL5017240 | 0.81 | CYP2A6 (0.43) | MAPTARCYP2A6CYP2C9CYP2B6 | |
| SCHEMBL5016843 | 0.81 | AR (0.45) | NAMPTMAPTARCYP2A6CYP2C9 | |
| SCHEMBL4260988 | 0.81 | CYP2A6 (0.43) | NAMPTMAPTARCYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833078-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| CN-102174017-A | Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions | AVENTIS PHARMA SA | 2011-09-07 | — | — | CN | claimed |
| US-7524838-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2009-04-28 | — | — | US | claimed |
| EP-1689720-B1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2009-04-15 | — | — | EP | claimed |
| CN-1906172-A | Pyrazole derivatives as medicaments for the treatment of acute or chronic neuronal degeneration | AVENTIS PHARMA SA (FR) | 2007-01-31 | — | — | CN | claimed |
| EP-1689720-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | Aventis Pharma S.A. (FR) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051917-A9 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2005-09-29 | — | — | WO | claimed |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | claimed |
| CN-1165546-C | New derivative of erythromycin, its preparation method and medicinal application | ���˹��ء���³�� | 2004-09-08 | — | — | CN | claimed |
| US-6664398-B2 | Reacting a derivative of erythromycin containing imidazole-1-ylcaroxylate with a pyrazolealkylamine derivative, to form a desired antibiotic | AVENTIS PHARMA S.A. (FR) | 2003-12-16 | — | — | US | claimed |
| EP-1004592-B1 | Derivatives of erythromycin, their process of preparation and their application as medicaments | AVENTIS PHARMA SA (FR) | 2003-07-16 | — | — | EP | claimed |
| US-20030050254-A1 | Reacting a derivative of erythromycin containing imidazole-1-ylcaroxylate with a pyrazolealkylamine derivative, to form a desired antibiotic | HOECHST MARION ROUSSEL | 2003-03-13 | — | — | US | claimed |
| CN-1263101-A | New derivative of erythromycin, its preparation method and medicinal application | HOECHST MARION ROUSSEL INC (FR) | 2000-08-16 | — | — | CN | claimed |
| EP-1004592-A1 | Derivatives of erythromycin, their process of preparation and their application as medicaments | HOECHST MARION ROUSSEL (FR) | 2000-05-31 | — | — | EP | claimed |
| US-8048893-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2011-11-01 | — | — | US | disclosed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| US-20030050254-A1 | Reacting a derivative of erythromycin containing imidazole-1-ylcaroxylate with a pyrazolealkylamine derivative, to form a desired antibiotic | HOECHST MARION ROUSSEL | 2003-03-13 | — | — | US | disclosed |
| US-6440941-B1 | REACTION WITH AMINOALKYL-SUBSTITUTED 1H-PYRAZOLE | AVENTIS PHARMA S.A. (FR) | 2002-08-27 | — | — | US | disclosed |
| EP-1004592-A1 | Derivatives of erythromycin, their process of preparation and their application as medicaments | HOECHST MARION ROUSSEL (FR) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1R, CBR3, C3AR1 | NAMPT 2908/4885TLR8 3449/4885HRH1 94/4885 |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | C1R, CBR3, C3AR1 | NAMPT 2860/4885TLR8 3511/4885HRH1 92/4885 |
| US-20030050254-A1 | Reacting a derivative of erythromycin containing imidazole-1-ylcaroxylate with a pyrazolealkylamine derivative, to form a desired antibiotic | CBR3, AADAC, KYAT3 | NAMPT 4380/4885TLR8 2311/4885HRH1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.